T-cell engager (TCE) specialist Candid Therapeutics has entered a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s rare disease maternal ...

Transformative Biotech LLC, a Boulder-based company working to develop faster molecular tests for diseases such as COVID-19 and cancer, has appointed Mark Kelleher as executive vice president of ...

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic ...

Industry leaders met in San Diego to debate whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

Eli Casdin, Casdin Capital CEO, joins 'Closing Bell' to discuss the biotech sector, the stocks Casdin favors and much more.

This biotech powerhouse could maintain its strength for the long term.

Come to the Biotech Career & Futures Fair, where representatives of top biotech and biopharmaceutical companies will discuss their current and future job openings. The event is open to all Wake Tech ...